Pretreatment platelet count improves the prognostic performance of the TNM staging system and aids in planning therapeutic regimens for nasopharyngeal carcinoma: a single-institutional study of 2,626 patients by unknown
Chen et al. Chinese Journal of Cancer  (2015) 34:1 
DOI 10.1186/s40880-015-0006-xORIGINAL ARTICLE Open AccessPretreatment platelet count improves the
prognostic performance of the TNM staging
system and aids in planning therapeutic regimens
for nasopharyngeal carcinoma: a single-
institutional study of 2,626 patients
Yu-Pei Chen1,2†, Bing-Cheng Zhao1,2†, Chen Chen1,2†, Lu-Jun Shen1,2, Jin Gao3, Zhuo-Yao Mai1,2, Meng-Kun Chen1,2,
Gang Chen1,2, Fang Yan1,2, Su Liu2 and Yun-Fei Xia1,4*Abstract
Introduction: Thrombocytosis has been identified as an unfavorable prognostic factor in several types of cancer.
This study aimed to evaluate the prognostic value of pretreatment platelet count in association with the TNM
staging system and therapeutic regimens in patients with nasopharyngeal carcinoma (NPC).
Methods: A total of 2,626 patients with NPC were retrospectively analyzed. Platelet count >300 × 109/L was defined as
thrombocytosis. Matched-pair analysis was performed between patients receiving chemoradiotherapy and radiotherapy.
Results: Multivariate analysis showed that platelet count was an independent unfavorable prognostic factor for
overall survival (OS) [hazard ratio (HR) = 1.810, 95% confidence interval (CI) = 1.531–2.140, P < 0.001] and distant
metastasis–free survival (DMFS) (HR = 1.873, 95% CI = 1.475–2.379, P < 0.001) in the entire patient cohort. Further
subgroup analysis revealed that increased platelet count was an independent unfavorable prognostic factor for OS and
DMFS in patients with NPC stratified by early and advanced T category, N category, or TNM classification (all P ≤ 0.001).
Receiver operating characteristic (ROC) curves verified that the predictive value of TNM classification for OS was improved
when combined with pretreatment platelet count (P = 0.030). Matched-pair analysis showed that chemoradiotherapy
significantly improved OS only in advanced-stage NPC with thrombocytosis (HR = 0.416, 95% CI = 0.226–0.765, P = 0.005).
Conclusions: Pretreatment platelet count, when combined with TNM classification, is a useful indicator for metastasis and
survival in patients with NPC. It may improve the predictive value of the TNM classification and help to identify patients
likely to benefit from more aggressive therapeutic regimens.
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Nasopharyngeal carcinoma (NPC) is a head and neck
cancer that shows a distinct endemic distribution, with a
high prevalence in southern China and surrounding areas
[1]. Radiotherapy is the mainstay treatment modality for* Correspondence: xiayf@sysucc.org.cn
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unless otherwise stated.NPC. With the advent of intensity-modulated radiation
therapy (IMRT), local control for NPC has improved
significantly, and distant metastasis is the main cause of
treatment failure at present [2].
Currently, the prognosis of patients with NPC is evalu-
ated primarily with the TNM staging system, which is
the most important prognostic factor. However, a
discrepancy sometimes exists between actual treatment
outcomes and TNM classifications. This happens be-
cause metastasis is predisposed to occur in some
patients with early-stage cancers, whereas a relatively
long-term survival may be observed in certain patientshis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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former group of patients, radiotherapy alone may be insuf-
ficient and is likely to end with failure; for the latter group
of patients, aggressive treatment such as chemoradiother-
apy may result in overtreatment, which causes toxicity,
decreases quality of life, and even increases the risk of non-
cancer death [5]. This phenomenon highlights limitations
of the TNM staging system, which does not take functional
factors into consideration. Hence, to improve the potential
for individualized treatment, it is reasonable to consider
other factors in addition to the TNM staging system for
more accurate and practical prognostication for NPC [6].
Platelets play important roles in physiological and
pathological pathways and have been linked to tumor
metastasis and other oncological processes. Tumor-
related thrombocytosis is a common phenomenon in pa-
tients with solid cancers, and it has been identified as an
unfavorable prognostic factor in lung cancer, breast can-
cer, and many other malignancies [7]. To our knowledge,
however, few studies have investigated the characteristics
and outcomes of patients with NPC and thrombocytosis.
Previously, we analyzed 1,582 patients with NPC and de-
termined that a platelet count greater than 300 × 109/L
before radiotherapy was an unfavorable prognostic factor
for survival and distant metastasis [8]. However, the out-
dated 2002 Union for International Cancer Control/
American Joint Committee on Cancer (UICC/AJCC) sta-
ging system was used in that study, and the association
between platelet count and the TNM classification was
not fully investigated, providing no evidence of whether
platelet count could be used together with the TNM
staging system to improve prognostic prediction. Also,
as we know, patients with advanced-stage NPC often re-
quire chemoradiotherapy, and chemotherapy may inhibit
marrow function and affect platelet count before radio-
therapy. Thus, in this study, we enlarged the sample size,
restaged all patients according to the newest 7th edition
of the UICC/AJCC staging system, and obtained platelet
count data before treatment (chemoradiotherapy or
radiotherapy) to accurately investigate the significance
and prognostic value of pretreatment platelet count for
treatment outcomes compared with established prognos-
tication systems. Moreover, adding chemotherapy to
radiotherapy helps to reduce the risk of metastasis in pa-
tients with NPC. Thus, we performed matched-pair ana-
lysis between patients who received chemoradiotherapy
and those who received radiotherapy alone to assess the
real effect of these treatments and to aid in planning
individualized treatment.
Patients and Methods
Patient selection and clinical staging
We conducted a retrospective study of 2,669 patients
who were newly diagnosed with NPC without distantmetastasis between January 2001 and December 2004 at
the Sun Yat-sen University Cancer Center (SYSUCC).
Inclusion criteria were as follows: (1) newly diagnosed,
histologically proven NPC; (2) no distant metastasis; and
(3) receiving radical radiotherapy. Exclusion criteria were
as follows: (1) lack of pretreatment platelet count
records (n = 12) and (2) concomitant diseases that may
affect platelet count, such as autoimmune disease,
history of blood transfusion, liver cirrhosis, and severe
hypertension (n = 31). Thus, a total of 2,626 patients
were included and their data were analyzed in this study.
Computed tomography and/or magnetic resonance
imaging was essential for disease staging before treat-
ment, and all cases were restaged according to the 7th
edition of the UICC/AJCC staging system [9]. This
study was approved by the Hospital Ethics Committee
of SYSUCC. Written consent was waived as it was a
retrospective study, and verbal consent was obtained
via telephone.Platelet count measurement
Pretreatment platelet count was measured at baseline
within 7 days before treatment (chemoradiotherapy or
radiotherapy) for all patients. A platelet count greater
than 300 × 109/L was defined as thrombocytosis, accord-
ing to the normal range of platelet counts in our institu-
tion (100 × 109/L to 300 × 109/L).Grouping and matching
The flowchart of our study design is shown in Figure 1.
We first performed survival analysis based on pretreat-
ment platelet count in all 2,626 patients with NPC.
Then, patients were categorized into 4 groups to
analyze the prognostic value of pretreatment platelet
count when stratified by T category, N category, and
TNM classification as follows: Group 1, T1–2/N0/
stages I–II disease with platelet count ≤300 × 109/L;
Group 2, T1–2/N0/stages I–II disease with platelet
count >300 × 109/L; Group 3, T3–T4/N1–3/stages
III–IV disease with platelet count ≤300 × 109/L; and
Group 4, T3–T4/N1–3/stages III–IV disease with platelet
count >300 × 109/L.
To balance other prognostic factors and validate the
real association between therapeutic regimens and treat-
ment outcomes in patients in the 4 groups, we per-
formed a one-to-one match between patients receiving
chemoradiotherapy and radiotherapy based on the
randomization pairing principle for matched-pair ana-
lysis. Matching was performed according to age, sex,
TNM classification, T category, and N category. We gen-
erated 743 matched pairs of patients, with 270 pairs in
Group 1, 34 pairs in Group 2, 379 pairs in Group 3, and
60 pairs in Group 4.
Figure 1 Flowchart of study design. NPC, nasopharyngeal carcinoma; ROC, receiver operating characteristic; CRT, chemoradiotherapy;
RT, radiotherapy.
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All patients were treated with definitive-intent radiother-
apy with high-energy, 6 MV to 8 MV X-ray by linear ac-
celerator, including 2,400 patients (91.4%) treated with
two-dimensional conformal radiotherapy (2D-CRT), 61
(2.3%) treated with three-dimensional conformal radio-
therapy (3D-CRT), and 165 (6.3%) treated with IMRT.
Opposing lateral facial-cervical fields were used in the
2D-CRT to cover the nasopharynx and upper cervical
lymphatic drainage region, with one lower anterior
cervical field to cover the lower cervical region. After 36
to 40 Gy of radiation, opposing lateral preauricular fields
were used for the primary region, and anterior split neck
fields were used for the cervical region. The primary
tumor was irradiated to a dose of 60 to 78 Gy. The dose
of prophylactic irradiation for patients treated with 2D-
CRT was 50 to 54 Gy to the prophylactic areas. For 3D-
CRT, the total prescribed dose was 66 to 72 Gy to the
gross tumor volume of the nasopharynx (GTVnx), 60 to
70 Gy to the gross tumor volume of the involvedmetastatic lymph nodes (GTVnd), 60 Gy to clinical tar-
get volumes-1 (CTV-1, the GTVnx and an additional 5-
to 10-mm margin), and 50 to 54 Gy to the prophylactic
irradiating region (CTV-2). For IMRT, the target defin-
ition and delineation were the same as described above
for 3D-CRT. The prescription dose was 68 Gy to the
GTVnx, 60 to 64 Gy to the GTVnd of the neck, 60 Gy
to the CTV-1, and 54 Gy to the CTV-2.
Chemotherapy
Of 2,626 patients, 1,216 (46.3%) received neoadjuvant,
concurrent, or adjuvant chemotherapy. The majority of
the patients (774 of 1,100; 70.3%) with stage III or IV
NPC (classified as T3–4 and/or N2–3 disease) received
chemotherapy. Neoadjuvant or adjuvant chemotherapy
consisted of cisplatin and 5-fluorouracil or taxanes every
3 weeks for 2 or 3 cycles. Concurrent chemotherapy
consisted of either cisplatin plus 5-fluorouracil or cis-
platin alone given weekly or on weeks 1, 4, and 7 of
radiotherapy.
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After completing treatment, patients were followed up
every 3 months for the first 3 years and the intervals
gradually increased to 6 to 12 months after 3 years.
February 1st, 2011 was the date of last follow-up.
The primary endpoint was overall survival (OS), and
the secondary endpoints were locoregional recurrence–
free survival (LRFS) and distant metastasis–free survival
(DMFS). OS was calculated as the period from the start
of treatment to death from any cause. LRFS and DMFS
were calculated as the period from the start of treatment
to the first occurrence of locoregional and distant
failure, respectively.Table 1 Baseline characteristics in the entire cohort of






PLT count [n (%)]
≤300 × 109/L >300 × 109/L P value
Age (years) 0.202
≤45 1,308 (49.8) 1,096 (49.3) 212 (52.7)
>45 1,318 (50.2) 1,128 (50.7) 190 (47.3)
Sex <0.001
Male 2,015 (76.7) 1,740 (78.2) 275 (68.4)
Female 611 (23.3) 484 (21.8) 127 (31.6)
TNM classification 0.021
I 157 ( 6.0) 134 ( 6.0) 23 ( 5.7)
II 899 (34.2) 778 (35.0) 121 (30.1)
III 1,036 (39.5) 882 (39.7) 154 (38.3)
IV 534 (20.3) 430 (19.3) 104 (25.9)
T category <0.001Statistical analysis
All analyses were performed using SPSS software,
version 19.0. The Chi-square test was used to compare
categorical variables. The rates of OS, LRFS, and DMFS
were estimated by means of the Kaplan-Meier method
and differences were compared by using the log-rank
test. Multivariate analysis using a Cox proportional
hazards model was used to test the independent sig-
nificance of different variables by backward elimin-
ation. The covariates entering into the multivariable
analysis included host factors (age and sex), tumor
factors (T and N categories), and treatment factor
(chemoradiotherapy or radiotherapy) for the entire
patient cohort and the 4 patient groups, and host
factors and tumor factors for matched pairs of
patients.
Receiver operating characteristic (ROC) curve ana-
lysis was used to evaluate the predicted validity of
pretreatment platelet count, based on the method of
Hanley and McNeil [10,11]. The comparison of areas
under the curve (AUCs) was made by Z test, and a
two-sided P value of < 0.05 was considered statistically
significant.T1 516 (19.6) 449 (20.2) 67 (16.7)
T2 1,010 (38.5) 870 (39.1) 140 (34.8)
T3 655 (24.9) 557 (25.0) 98 (24.4)
T4 445 (16.9) 348 (15.6) 97 (24.1)
N category 0.616
N0 669 (25.5) 566 (25.4) 103 (25.6)
N1 1,081 (41.2) 920 (41.4) 161 (40.0)
N2 773 (29.4) 647 (29.1) 126 (31.3)
N3 103 (3.9) 91 ( 4.1) 12 (3.0)
Treatment 0.652
CRT 1,216 (46.3) 1,034 (46.5) 182 (45.3)
RT 1,410 (53.7) 1,190 (53.5) 220 (4.7)
Total 2,626 2,223 402
PLT, platelet; CRT, chemoradiotherapy; RT, radiotherapy.Results
Patient characteristics
The baseline characteristics of the 2,626 patients ana-
lyzed in this study are shown in Table 1. The median
age was 46 years (range, 11–78 years). Among the
2,626 patients, 2,387 (90.9%) had undifferentiated non-
keratinizing carcinoma, 222 (8.4%) had differentiated
non-keratinizing carcinoma, and 17 (0.6%) had other
types of cancer.
The median duration of follow-up was 81.6 months
(range, 1.4–124.7 months). Of all 2,626 patients, 493
(18.8%) developed locoregional failure, 368 (14.0%) de-
veloped distant metastasis, and 774 (29.5%) died. For the
entire cohort, the 5-year OS, LRFS, and DMFS rates
were 76.7%, 84.4%, and 86.7%, respectively.Characteristics and survival analysis in the entire patient
cohort
Pretreatment platelet count ranged from 58 × 109/L to
572 × 109/L with a median value of 224 × 109/L. Among
all 2,626 patients, 402 (15.3%) had a platelet count
greater than 300 × 109/L. Thrombocytosis occurred
more frequently in female patients than in male patients
(20.8% vs. 13.6%, P < 0.001), in patients with advanced
T-category (T3–4) lesions than in patients with early
T-category (T1–2) lesions (17.7% vs. 13.6%, P < 0.001),
and in patients with locoregionally advanced NPC
(stages III–IV) than in patients with early-stage NPC
(stages I–II) (16.4% vs. 13.6%, P = 0.021) (Table 1). No
significant differences in age, N category, or treatment
were found.
Univariate analysis indicated that platelet count was a
significant prognostic factor for OS (P < 0.001) and
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multivariate analysis, platelet count was an independent
unfavorable prognostic factor for OS [hazard ratio (HR)
= 1.810, 95% confidence interval (CI) = 1.531–2.140, P <
0.001] and DMFS (HR = 1.873, 95% CI = 1.475–2.379, P
< 0.001).Subgroup analysis in patients stratified by T category/N
category/TNM classification
Stratified by T category, patients in Group 1 and Group
2 had 5-year OS rates of 81.3% and 72.9% (P < 0.001),
respectively, and 5-year DMFS rates of 88.6% and 79.8%
(P = 0.001), respectively; in patients in Group 3 and
Group 4, the 5-year OS rates were 73.7% and 64.3% (P <
0.001), respectively (Figures 2A), and the 5-year DMFS
rates were 87.3% and 78.0% (P < 0.001), respectively
(Figures 2B). Stratified by N category, patients in Group
1 and Group 2 had 5-year OS rates of 86.5% and 81.3%
(P = 0.001), respectively, and a 5-year DMFS rates of
95.0% and 85.5% (P = 0.004), respectively; in patients in
Group 3 and Group 4, the 5-year OS rates were 75.3%
and 64.2% (P < 0.001), respectively (Figures 2C), and the
5-year DMFS rates were 85.6% and 76.6% (P < 0.001),
respectively (Figures 2D). For LRFS, no significant differ-
ence was found between patients with different platelet
counts after T/N category stratification. Multivariate
analysis showed that a high platelet count was an
independent unfavorable prognostic factor for OS and
DMFS not only in patients with advanced T/N categor-
ies (Group 3 and Group 4) but also in patients with
early T/N categories (Group 1 and Group 2) (all P ≤
0.001).
Stratified by TNM classification, patients in Group 1
and Group 2 had 5-year OS rates of 85.2% and 77.1%
(P < 0.001), respectively, and 5-year DMFS rates of
90.5% and 82.6% (P = 0.008), respectively; in patients in
Group 3 and Group 4, the 5-year OS rates were 73.3%
and 63.9% (P < 0.001), respectively (Figure 2E), and the
5-year DMFS rates were 86.3% and 76.8% (P < 0.001),
respectively (Figure 2F). Overall, the 5-year OS and
DMFS rates of patients with different platelet counts
were significantly different when stratified by TNM
classification (Group 1 vs. Group 2; Group 3 vs. Group
4). However, no significant difference was found be-
tween Group 2 and Group 3. For LRFS, no significant
difference was observed between patients with different
platelet counts when stratified by TNM classification.
In multivariate analysis, a high platelet count was an
independent unfavorable prognostic factor for OS and
DMFS not only in patients with locoregionally ad-
vanced NPC (Group 3 and Group 4) but also in
patients with early-stage NPC (Group 1 and Group 2)
(all P ≤ 0.01; Table 2).The validity of adding pretreatment platelet count to
TNM classification for predicting survival in the entire
patient cohort
ROC curves were used to compare the validity of adding
pretreatment platelet count (≤300 × 109/L and >300 ×
109/L) to TNM classification (stages I–II and III–IV) for
prognostic prediction. For OS, the AUC was 0.58 for
TNM classification alone and 0.61when platelet count
was added to TNM classification (P = 0.030) (Figure 3A).
The results revealed that the addition of platelet count
to TNM classification was superior to TNM classifica-
tion alone in predicting survival for patients with NPC.
No significant improvement in predicting locoregional
recurrence was observed with the addition of platelet
count to TNM classification (P = 0.393) (Figure 3B). For
DMFS, adding platelet count to TNM classification had
a tendency to improve prediction of distant metastasis
(P = 0.086) (Figure 3C).
Prognostic value of chemoradiotherapy in matched pairs
of patients in the 4 groups stratified by TNM classification
The baseline characteristics of the 743 matched pairs of
patients are shown in Table 3. In Group 1, the 5-year
OS, LRFS, and DMFS rates for patients receiving radio-
therapy and chemoradiotherapy were 80.1% vs. 80.8%
(P = 0.623), 91.6% vs. 90.2% (P = 0.284), and 87.6% vs.
85.0% (P = 0.198). In Group 2, the 5-year OS, LRFS, and
DMFS rates for patients receiving radiotherapy and che-
moradiotherapy were 59.8% vs. 73.5% (P = 0.337), 90.0%
vs. 96.0% (P = 0.378), and 65.1% vs. 87.2% (P = 0.068).
In Group 3, the 5-year OS, LRFS, and DMFS rates for
patients receiving radiotherapy and chemoradiotherapy
were 70.7% vs. 78.3% (P = 0.085), 79.4% vs. 84.7% (P =
0.175), and 88.2% vs. 88.9% (P = 0.772). There was no
significant difference among the treatment outcomes for
the aforementioned 3 groups. In Group 4, the 5-year
OS, LRFS, and DMFS rates for patients receiving radio-
therapy and chemoradiotherapy were 63.3% vs. 75.0%
(P = 0.002), 79.3% vs. 88.1% (P = 0.008), and 72.7% vs.
84.6% (P = 0.009), indicating a significant difference for
all treatment outcomes (Figure 4). Cox regression also
showed that chemoradiotherapy significantly improved
OS (HR = 0.416, 95% CI = 0.226–0.765, P = 0.005),
LRFS (HR = 0.327, 95% CI = 0.130–0.820, P = 0.017),
and DMFS (HR = 0.366, 95% CI = 0.162–0.825, P =
0.015) in Group 4.
Discussion
Pretreatment platelet count is a common and practical
laboratory examination. This study demonstrates that
thrombocytosis was associated with poor OS (HR = 1.810,
95% CI = 1.531–2.140, P < 0.001) and increased the inci-
dence of distant metastasis (HR = 1.873, 95% CI = 1.475–
2.379, P < 0.001) in patients with NPC. Thrombocytosis
Figure 2 Survival analysis based on pretreatment platelet count (≤300 × 109/L and >300 × 109/L) in all 2,626 patients with
nasopharyngeal carcinoma stratified by T category/N category/TNM classification. A, overall survival curves for the 4 groups stratified by T
category. B, distant metastasis–free survival curves for the 4 groups stratified by T category. C, overall survival curves for the 4 groups stratified by
N category. D, distant metastasis–free survival curves for the 4 groups stratified by N category. E, overall survival curves for the 4 groups stratified
by TNM classification. F, distant metastasis–free survival curves for the 4 groups stratified by TNM classification. Group 1: T1–2/N0/stages I–II
disease with platelet count ≤300 × 109/L; Group 2: T1–2/N0/stages I–II disease with platelet count >300 × 109/L; Group 3: T3–4/N1–3/stages
III–IV disease with platelet count ≤300 × 109/L; Group 4: T3–4/N1–3/stages III–IV disease with platelet count >300 × 109/L.
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Table 2 Multivariate analyses of prognostic factors for patients with early-stage and locoregionally advanced NPC
Endpoint Variablea HR 95% CI P value
Early-stage NPC (n = 1,057)
Overall survival Age (>45 vs. ≤45 years) 1.586 1.213–2.075 0.001
Sex (female vs. male) 1.409 1.019–1.949 0.038
T category (T2 vs. T1) 1.352 1.014–1.803 0.040
N category (N1 vs. N0) 2.326 1.732–3.124 <0.001
PLT count (>300 × 109/L vs. ≤300 × 109/L) 2.057 1.510–2.804 <0.001
Locoregional recurrence–free survival N category (N1 vs. N0) 1.566 1.053–2.328 0.027
Distant metastasis–free survival Age (>45 vs. ≤45 years) 1.387 0.970–1.984 0.073
T category (T2 vs. T1) 1.899 1.249–2.888 0.003
N category (N1–3 vs. N0) 2.532 1.677–3.824 <0.001
PLT count (>300 × 109/L vs. ≤300 × 109/L) 1.788 1.167–2.739 0.008
Locoregionally advanced NPC (n = 1,569)
Overall survival Age (>45 vs. ≤45 years) 1.657 1.397–1.966 <0.001
Gender (female vs. male) 1.452 1.163–1.813 0.001
PLT count (>300 × 109/L vs. ≤300 × 109/L) 1.716 1.407–2.093 <0.001
Locoregional recurrence–free survival Age (>45 vs. ≤45 years) 1.541 1.238–2.037 <0.001
Gender (female vs. male) 1.561 1.259–1.888 0.001
Distant metastasis–free survival N category (N1–3 vs. N0) 2.014 1.331–3.047 0.001
PLT count (>300 × 109/L vs. ≤300 × 109/L) 1.859 1.393–2.481 <0.001
aThe parameters listed in this column were included in the multivariate analysis using Cox proportional hazards model by backward elimination. PLT, platelet; CRT,
chemoradiotherapy; RT, radiotherapy; HR, hazard ratio; CI, confidence interval.
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subgroup analysis stratified by T category/N category/
TNM classification. Thrombocytosis was more frequent in
patients with advanced-stage disease, occurring in 13.6%
(144 of 1,056) of patients with early-stage NPC (stages I–II)
and in 16.4% (257 of 1,570) of patients with locoregionally
advanced NPC (stages III–IV) (P = 0.021).Figure 3 Receiver operating characteristic (ROC) curves for survival p
with the addition of pretreatment platelet count ( ≤300 × 109/L and >
nasopharyngeal carcinoma. A, overall survival. B, locoregional recurrence
comparison of area under the curves (AUCs) between the addition of plateIncreased platelet count can be commonly observed
in malignancies (10% to 57%) [12]. The cause of
tumor-related thrombocytosis still remains unclear but
interleukin-6 (IL-6) is thought to be responsible, as it
mediates tumor-related production of thrombopoietin, a
granulocyte-macrophage colony-stimulating factor [13].
Accumulating evidence shows that increased plateletrediction with TNM classification alone (stages I–II and III–IV) or
300 × 109/L) to TNM classification in the 2,626 patients with
–free survival. C, distant metastasis–free survival. The P value was the
let count to TNM classification and TNM classification alone.
Table 3 Baseline characteristics in matched pairs of patients with NPC
Patient
characteristic
Group 1 (N = 270 pairs) Group 2 (N = 34 pairs) Group 3 (N = 379 pairs) Group 4 (N = 60 pairs)
RT [n (%)] CRT [n (%)] RT [n (%)] CRT [n (%)] RT [n (%)] CRT [n (%)] RT [n (%)] CRT [n (%)]
Age (years)
≤45 138 (51.1) 138 (51.1) 18 (52.9) 18 (52.9) 171 (45.1) 171 (45.1) 31 (51.7) 31 (51.7)
>45 132 (48.9) 132 (48.9) 16 (47.1) 16 (47.1) 208 (54.9) 208 (54.9) 29 (48.3) 29 (48.3)
Sex
Male 71 (26.3) 71 (26.3) 8 (23.5) 8 (23.5) 79 (20.8) 79 (20.8) 15 (25.0) 15 (25.0)
Female 199 (73.7) 199 (73.7) 26 (76.5) 26 (76.5) 300 (79.2) 300 (79.2) 45 (75.0) 45 (75.0)
TNM classification
I 4 (1.5) 4 (1.5) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
II 266 (98.5) 266 (98.5) 34(100.0) 34 (100.0) 0 (0) 0 (0) 0 (0) 0 (0)
III 0 (0) 0 (0) 0 (0) 0 (0) 293 (77.3) 293 (77.3) 39 (65.0) 39 (65.0)
IV 0 (0) 0 (0) 0 (0) 0 (0) 86 (22.7) 86 (22.7) 21 (35.0) 21 (35.0)
T category
T1 72 (26.7) 72 (26.7) 9 (26.5) 9 (26.5) 38 (10.0) 38 (10.0) 3 (5.0) 3 (5.0)
T2 198 (73.3) 198 (73.3) 25 (73.5) 25 (73.5) 92 (24.3) 92 (24.3) 12 (20.0) 12 (20.0)
T3 0 (0) 0 (0) 0 (0) 0 (0) 167 (44.1) 167 (44.1) 24 (40.0) 24 (40.0)
T4 0 (0) 0 (0) 0 (0) 0 (0) 82 (21.6) 82 (21.6) 21 (35.0) 21 (35.0)
N category
N0 28 (10.4) 28 (10.4) 3 (8.8) 3 (8.8) 87 (23.0) 87 (23.0) 10 (16.7) 10 (16.7)
N1 242 (89.6) 242 (89.6) 31 (91.2) 31 (91.2) 103 (27.2) 103 (27.2) 20 (33.3) 20 (33.3)
N2 0 (0) 0 (0) 0 (0) 0 (0) 185 (48.8) 185 (48.8) 30 (50.0) 30 (50.0)
N3 0 (0) 0 (0) 0 (0) 0 (0) 4 (1.1) 4 (1.1) 0 (0) 0 (0)
CRT, chemoradiotherapy; RT, radiotherapy. Group 1: early-stage disease with platelet count ≤300 × 109/L; Group 2: early-stage disease with platelet count >300 ×
109/L; Group 3: locoregionally advanced disease with platelet count ≤300 × 109/L; Group 4: locoregionally advanced disease with platelet count >300 × 109/L.
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by facilitating immune evasion, promoting extravasation,
and impeding natural killer cells [4]. The association be-
tween thrombocytosis and TNM classification indicates
an interaction between platelets and tumor cells inFigure 4 Survival analysis based on treatment [chemoradiotherapy (C
stages III–IV nasopharyngeal carcinoma and platelet count >300 × 10
distant metastasis–free survival. Hazards ratios (HRs) were calculated using
calculated using the unadjusted log-rank test.tumor progression. Platelets can secrete a number of
proangiogenic cytokines such as vascular endothelial
growth factor [14] and thymidine phosphorylase [15].
These platelet-derived factors regulate angiogenesis and
cell proliferation, which are associated with extensiveRT) and radiotherapy (RT)] in matched pairs of patients with
9/L. A, overall survival. B, locoregional recurrence–free survival. C,
the unadjusted Cox proportional hazards model. P values were
Chen et al. Chinese Journal of Cancer  (2015) 34:1 Page 9 of 10tumor invasion and poor response to chemoradiotherapy
[16,17]. Advanced cancer can further induces the
production and activation of platelets through tumor-
associated tissue factors such as IL-6, thrombin, and
ADP, thus creating a vicious circle [18]. Similar associ-
ation between thrombocytosis and TNM classification
was also found in other solid cancers [19-21]. Along
with proangiogenic cytokines, platelets also promote
angiogenesis directly via integrins by mediating cell-to-
cell adhesion [22] and increasing the risk of thrombosis
through the hypercoagulable state developed in cancer
patients [23] and therefore result in poor prognosis.
Another major objective of our study was to verify the
prognostic value of both pretreatment platelet count and
disease stage. Although advanced-stage disease is usually
associated with poor local control and survival, patients
with different platelet counts and tumors in the same
TNM classification may have different prognoses. In the
stratified analysis, patients with tumors in the same
TNM classification (early-stage or advanced) and differ-
ent platelet counts had significantly different OS and
DMFS. Notably, there was no significant difference in
OS and DMFS between patients with early-stage NPC
with thrombocytosis (Group 2) and those with locore-
gionally advanced NPC without thrombocytosis (Group
3). This reiterates the limitations of the current TNM
staging system, which is based on anatomic involvement
and does not accurately reflect the level of malignancy.
Increased pretreatment platelet count may reflect in-
creased tumor burden and result in poor prognosis
beyond the TNM staging system. The ROC curve results
suggest that the prediction of survival can be signifi-
cantly improved by adding pretreatment platelet count
to the current TNM staging system (P = 0.030). Also,
adding platelet count to TNM classification had a strong
tendency to improve the prediction of distant metastasis
(P = 0.086). Such improvements to the prognostic sys-
tem would facilitate better stratification such that
patients with predicted poorer prognosis could receive
more aggressive treatment protocols.
From the results of matched-pair analysis between
patients receiving different therapeutic regimens, we can
see that chemoradiotherapy did not improve any treat-
ment outcome in patients with early-stage NPC with or
without thrombocytosis (Group 1 and Group 2) al-
though there was a strong tendency to reduce the risk of
distant metastasis in Group 2 (P = 0.078). For patients
with locoregionally advanced NPC without thrombocy-
tosis (Group 3), chemoradiotherapy had a strong ten-
dency to improve survival (P = 0.093), and for patients
with locoregionally advanced NPC with thrombocytosis
(Group 4), chemoradiotherapy improved all treatment
outcomes. One major goal of adding chemotherapy to
radiotherapy in patients with NPC is to reducemicrometastases. The results above indicate that pre-
treatment platelet count can serve as a useful tool to
identify patients at high risk of metastasis and poor sur-
vival, who could benefit from more aggressive treatment
such as chemoradiotherapy. Patients with early-stage
NPC without thrombocytosis may gain less or even no
benefit from aggressive therapeutic strategies, which
means chemoradiotherapy probably results in overtreat-
ment and the adverse effects outweigh the advantages.
In contrast, patients with early-stage NPC with throm-
bocytosis may benefit from chemoradiotherapy, as it has
a tendency to reduce the risk of metastasis. The insig-
nificant improvement in survival may result from the
relatively early-stage and small matched-pair samples.
As patients with advanced-stage NPC with thrombocy-
tosis may gain the most benefit from chemoradiother-
apy, it is possible that these patients may require a more
intensive systemic treatment. However, for patients with
advanced-stage NPC without thrombocytosis, clinicians
using current chemoradiotherapy strategies should
monitor for overtreatment and modulate the treatment
plan as necessary, as these patients stand to gain less
benefit. Moreover, with respect to thrombocytosis,
anticoagulants may be combined with radiotherapy or
chemoradiotherapy to improve treatment outcomes. A
meta-analysis of 11 studies demonstrated that anticoagu-
lants could significantly improve OS in cancer patients
[24].
This study has several limitations. This is a retrospect-
ive study, in which the results might be affected by some
confounding factors and the bias could not be neglected.
Also, the absolute difference between AUCs was rela-
tively small, indicating that platelet count alone was in-
sufficient for establishing an excellent predictive model.
Additional predictive factors are needed to improve the
model’s performance. Moreover, although previous
meta-analyses indicated that both neoadjuvant chemo-
therapy and concurrent chemotherapy with or without
adjuvant chemotherapy could improve OS in patients
with locoregionally advanced NPC [25,26], the demon-
strated superiority of chemoradiotherapy to radiotherapy
alone could be a mixed effect of the combined modal-
ities, which is hard to distinguish. In addition, only a
small proportion of patients (6.3%) received IMRT. As
IMRT can improve local control significantly, we pre-
sume that the predictive ability of pretreatment platelet
count for metastasis and survival would be more appar-
ent in patients receiving IMRT, and these patients may
gain more benefit from the addition of chemotherapy if
thrombocytosis is present. Despite these limitations, this
is a single-institution study with a large sample size that
specifically reports the prognostic value of pretreatment
platelet count in association with the TNM classification
\and therapeutic regimens in patients with NPC. The
Chen et al. Chinese Journal of Cancer  (2015) 34:1 Page 10 of 10results of this study could aid further refinement of the
current TNM staging system. Furthermore, pretreatment
platelet count, which can be measured easily and at low
cost, may aid in developing individualized treatment strat-
egies to improve the prognosis of patients with NPC and
therefore represents an important therapeutic prospect.Conclusions
Pretreatment platelet count is a useful indicator for me-
tastasis and survival in NPC patients. It helps to improve
the prediction accuracy of the TNM staging system.
Also, it is a useful tool to identify patients who may
benefit from more aggressive therapeutic regimens.
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